Science News
from research organizations

Eribulin and body mass in metastatic breast cancer: News from the hardest front of the battle

Date:
October 18, 2015
Source:
Sbarro Health Research Organization (SHRO)
Summary:
New research has brought metastatic breast cancer to the attention of the cancer research community when considering the drug Eribulin in relation to body mass, say Italian researchers.
Share:
FULL STORY

The recent publication of the manuscript entitled "Body mass index and treatment outcomes in metastatic breast cancer patients treated with Eribulin," which has just appeared in the "Journal of Cellular Physiology," has newly brought metastatic breast cancer to the attention of our cancer research community.

"The recent achievements in the scientific field have significantly widened the therapeutic options available against cancer. In some cases, which surely include breast cancer, the impact of new drugs on treatment outcomes has been undeniable in both the early and advanced phase of the disease." says Prof. Antonio Giordano, Director of the Sbarro Health Research Organization, Philadelphia, USA.

"Eribulin has proven survival advantage and manageable toxicity in women with heavily pre-treated metastatic breast cancer. The characterization of the patient profile more often associated with the best response in terms of efficacy may help maximize the therapeutic benefit at an individual patient level. The idea is that, for each and any therapeutic approach across the different settings, some patient features may be associated with better outcomes. Those "features" are the object of our interest. More specifically, our data show an impact of body mass index (BMI) on the outcomes considered, in that, patients whose BMI falls in the lowest category are more likely to remain "free" from disease progression for a longer time." Asserts Dr Maddalena Barba, senior researcher at Regina Elena Cancer Institute of Rome (Central Italy) and research coordinator for the project carried out by a multidisciplinary team composed by Italian and American members.

"Metastatic breast cancer remains particularly challenging and complex. In this setting, the understanding of the factors and mechanisms regulating patient response to treatment are of key importance." explains Prof. Giordano. "BMI is modifiable throughout lifestyle interventions and/or widely used drugs like metformin. Somewhat, the multifactorial nature of cancer has led us to consider multifactorial solutions, that is, solutions made of different "approaches." The battle against cancer is increasingly fought on multiple fronts, including diet- and physical exercise-related interventions, clinical research and practice. The all process needs to be particularly effective where we are majorly anger for patient important results, such as in metastatic breast cancer" clarifies and concludes the scientist.


Story Source:

Materials provided by Sbarro Health Research Organization (SHRO). Note: Content may be edited for style and length.


Journal Reference:

  1. Maddalena Barba, Laura Pizzuti, Isabella Sperduti, Clara Natoli, Teresa Gamucci, Domenico Sergi, Luigi Di Lauro, Luca Moscetti, Fiorentino Izzo, Massimo Rinaldi, Lucia Mentuccia, Angela Vaccaro, Laura Iezzi, Antonino Grassadonia, Andrea Michelotti, Letizia Perracchio, Edoardo Pescarmona, Franco Di Filippo, Antonio Giordano, Marcello Maugeri-Saccà, Patrizia Vici. Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated with Eribulin. Journal of Cellular Physiology, 2015; DOI: 10.1002/jcp.25213

Cite This Page:

Sbarro Health Research Organization (SHRO). "Eribulin and body mass in metastatic breast cancer: News from the hardest front of the battle." ScienceDaily. ScienceDaily, 18 October 2015. <www.sciencedaily.com/releases/2015/10/151018223243.htm>.
Sbarro Health Research Organization (SHRO). (2015, October 18). Eribulin and body mass in metastatic breast cancer: News from the hardest front of the battle. ScienceDaily. Retrieved May 24, 2017 from www.sciencedaily.com/releases/2015/10/151018223243.htm
Sbarro Health Research Organization (SHRO). "Eribulin and body mass in metastatic breast cancer: News from the hardest front of the battle." ScienceDaily. www.sciencedaily.com/releases/2015/10/151018223243.htm (accessed May 24, 2017).

RELATED STORIES